Cargando…
Global Introduction of New Multidrug-Resistant Tuberculosis Drugs—Balancing Regulation with Urgent Patient Needs
New treatments for multidrug-resistant tuberculosis (MDR TB) are urgently needed. Two new drugs, bedaquiline and delamanid, have recently been released, and several new drugs and treatment regimens are in the pipeline. Misuse of TB drugs is a principal cause of drug resistance. As new drugs and regi...
Autores principales: | Sullivan, Timothy, Ben Amor, Yanis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766896/ https://www.ncbi.nlm.nih.gov/pubmed/26889711 http://dx.doi.org/10.3201/eid2203.151228 |
Ejemplares similares
-
Underreported Threat of Multidrug-Resistant Tuberculosis in Africa
por: Ben Amor, Yanis, et al.
Publicado: (2008) -
Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis
por: Furin, Jennifer, et al.
Publicado: (2016) -
The Co-Management of Tuberculosis and Diabetes: Challenges and Opportunities in the Developing World
por: Sullivan, Timothy, et al.
Publicado: (2012) -
Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis
por: Campbell, Jonathon R., et al.
Publicado: (2020) -
Urgent need for novel antibiotics in Republic of Korea to combat multidrug-resistant bacteria
por: Lee, Hyo-Jin, et al.
Publicado: (2022)